Search

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Partnering for Innovation in Animal Health

Video with Erik Haaksma and Megan Grether describing how partnering is an essential component of innovation at Boehringer Ingelheim Animal Health.

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Management Rotation | Academic Programs

Management Rotation Program

Cardio-Renal-Metabolic diseases

From garbage to garden - Recycling organic waste to contribute to a healthier planet

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

Real-world study shows sequencing of Gilotrif

Saving Stroke Patients around the world

Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.

Achieving Health Equity: The Importance of Patient Input at Every Phase of Care

Learn more about how our BI Diversity and Inclusion Patient Council illuminates the impact of health inequities & how we can work together to be upstanders.

Cleaning up the coast for a greener future

Employees from our Fremont site connect with nature and clean up the environment.

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Six creative Connecticut students turn aspiring ideas into inventive innovation

Learn about the 2023 Connecticut Invention Convention winners.

What our partners say

Mental Disorders

Retinal Diseases

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

Kobe

The Kobe Pharma Research Institute takes part in the global research and development activities for human pharmaceuticals.

2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers